Table 5.
Multivariate logistic regression analyses to predict sarcopenia after neoadjuvant chemotherapy.
| Variable | Value | Coef. | 95% CI | p-value | |
|---|---|---|---|---|---|
| Baseline sarcopenia | Yes | 3.357 | 2.565 | 4.149 | .000 |
| No | 1.000 | ||||
| Baseline subcutaneous fat | -.007 | -.027 | .013 | .485 | |
| Baseline visceral fat | -.027 | -.056 | .001 | .058 | |
| Age at diagnosis | .008 | -.030 | .046 | .675 | |
| Chemotherapy regimen | AC-T regimen | 1.000 | |||
| TCHP regimen | 2.089 | -.237 | 4.415 | .078 | |
| Tumor subtype | HR+/HER2− | 1.000 | |||
| HR+/HER2+ | -.204 | -1.847 | 1.439 | .808 | |
| HR−/HER2+ | -.494 | -2.171 | 1.183 | .564 | |
| TNBC | .091 | -.781 | .963 | .838 | |
| Chemotherapy duration | .014 | -.017 | .045 | .368 | |
AC-T regimen, combination of an anthracycline and cyclophosphamide, followed by a taxane; CI, confidence interval; HER2−, human epidermal growth factor receptor 2-negative; HER2+, human epidermal growth factor receptor 2-positive; HR−, hormone receptor-negative; HR+, hormone receptor-positive; TCHP regimen, docetaxel, carboplatin, trastuzumab, and pertuzumab; TNBC, triple negative breast cancer. LR χ2(9) = 140.67, p <.000, pseudo R2 = 0.3908.